nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—PLA2G4A—Fluocinolone Acetonide—psoriasis	0.438	0.646	CbGbCtD
Epirubicin—UGT2B7—Mycophenolic acid—psoriasis	0.119	0.176	CbGbCtD
Epirubicin—UGT2B7—Mycophenolate mofetil—psoriasis	0.0665	0.0981	CbGbCtD
Epirubicin—ABCC1—Cyclosporine—psoriasis	0.0358	0.0528	CbGbCtD
Epirubicin—ABCC1—Methotrexate—psoriasis	0.0189	0.0279	CbGbCtD
Epirubicin—CHD1—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.00305	0.488	CbGdCrCtD
Epirubicin—DHCR7—Vitamin D Metabolism—VDR—psoriasis	0.00292	0.111	CbGpPWpGaD
Epirubicin—DHCR7—Activation of gene expression by SREBF (SREBP)—CARM1—psoriasis	0.00161	0.0614	CbGpPWpGaD
Epirubicin—Doxorubicin—NOS2—psoriasis	0.00154	1	CrCbGaD
Epirubicin—DHCR7—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CARM1—psoriasis	0.00129	0.0491	CbGpPWpGaD
Epirubicin—AURKA—APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1—PTTG1—psoriasis	0.00101	0.0385	CbGpPWpGaD
Epirubicin—AURKA—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.001	0.16	CbGdCrCtD
Epirubicin—AURKA—APC/C-mediated degradation of cell cycle proteins—PTTG1—psoriasis	0.000878	0.0335	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—NFKBIA—psoriasis	0.000648	0.0247	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000637	0.0243	CbGpPWpGaD
Epirubicin—AURKA—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000567	0.0907	CbGdCrCtD
Epirubicin—YWHAG—Cell Cycle—PTTG1—psoriasis	0.000553	0.0211	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000539	0.0206	CbGpPWpGaD
Epirubicin—TOP2A—G0 and Early G1—PCNA—psoriasis	0.000486	0.0185	CbGpPWpGaD
Epirubicin—YWHAG—FoxO family signaling—CAT—psoriasis	0.000471	0.0179	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—GJB2—psoriasis	0.000444	0.0169	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000356	0.0136	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000354	0.0135	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.00035	0.0133	CbGpPWpGaD
Epirubicin—AURKA—Calcipotriol—Calcitriol—psoriasis	0.000333	0.0532	CbGdCrCtD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—psoriasis	0.00033	0.0126	CbGpPWpGaD
Epirubicin—AURKA—Integrin-linked kinase signaling—JUN—psoriasis	0.000319	0.0122	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—psoriasis	0.000284	0.0108	CbGpPWpGaD
Epirubicin—AURKA—Calcipotriol—Cholecalciferol—psoriasis	0.000283	0.0453	CbGdCrCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL13—psoriasis	0.000281	0.0107	CbGpPWpGaD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—psoriasis	0.000273	0.0436	CbGdCrCtD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.00027	0.0103	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SERPINB8—psoriasis	0.000268	0.0102	CbGpPWpGaD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—psoriasis	0.000255	0.00974	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—NFKBIA—psoriasis	0.000248	0.00945	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000234	0.00894	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—PCNA—psoriasis	0.000226	0.0086	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000214	0.00816	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—NDUFA5—psoriasis	0.000206	0.00788	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—PCNA—psoriasis	0.000206	0.00784	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000204	0.00777	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000203	0.00774	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000197	0.00753	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000193	0.00734	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—PTTG1—psoriasis	0.000191	0.0073	CbGpPWpGaD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—psoriasis	0.000183	0.00697	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000179	0.00683	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000179	0.00683	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL10—psoriasis	0.000176	0.00671	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP2S1—psoriasis	0.000176	0.0067	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—psoriasis	0.000166	0.00631	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—JUN—psoriasis	0.000164	0.00627	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000164	0.00626	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—NFKBIA—psoriasis	0.000163	0.0062	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—NOS2—psoriasis	0.000163	0.0062	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000162	0.00619	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.000153	0.00582	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—psoriasis	0.00015	0.00574	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—PTTG1—psoriasis	0.000145	0.00553	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet homeostasis—NOS2—psoriasis	0.000142	0.00543	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—STAT3—psoriasis	0.000142	0.00542	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000126	0.00481	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—JUN—psoriasis	0.000123	0.00468	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000121	0.00462	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000118	0.00451	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000117	0.00445	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.000115	0.00438	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—JUN—psoriasis	0.000114	0.00437	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000113	0.00433	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—JUN—psoriasis	0.000112	0.00427	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000111	0.00422	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—JUN—psoriasis	0.000108	0.00411	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—JUN—psoriasis	0.000107	0.00407	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—STAT3—psoriasis	0.000106	0.00405	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000106	0.00404	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—NFKB1—psoriasis	0.000104	0.00396	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—PTTG1—psoriasis	0.000101	0.00387	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—STAT3—psoriasis	9.9e-05	0.00378	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—CXCL8—psoriasis	9.62e-05	0.00367	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	9.55e-05	0.00364	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—STAT3—psoriasis	9.33e-05	0.00356	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HCAR2—psoriasis	9.3e-05	0.00355	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—STAT3—psoriasis	9.24e-05	0.00352	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.2e-05	0.00351	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	8.99e-05	0.00343	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—JUN—psoriasis	8.94e-05	0.00341	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—PCNA—psoriasis	8.72e-05	0.00333	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	8.65e-05	0.0033	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—NFKB1—psoriasis	8.61e-05	0.00328	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CARM1—psoriasis	8.57e-05	0.00327	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—psoriasis	8.29e-05	0.00316	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	8.27e-05	0.00316	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—LEP—psoriasis	8.27e-05	0.00315	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	8.02e-05	0.00306	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.01e-05	0.00306	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—psoriasis	8e-05	0.00305	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.81e-05	0.00298	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—PCNA—psoriasis	7.8e-05	0.00298	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ITGAL—psoriasis	7.77e-05	0.00296	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—NOS2—psoriasis	7.7e-05	0.00294	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—PPARG—psoriasis	7.2e-05	0.00275	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NDUFA5—psoriasis	7.13e-05	0.00272	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NDUFA5—psoriasis	6.99e-05	0.00267	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.95e-05	0.00265	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TNF—psoriasis	6.73e-05	0.00257	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—TNF—psoriasis	6.7e-05	0.00255	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—PCNA—psoriasis	6.61e-05	0.00252	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—psoriasis	6.59e-05	0.00251	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.52e-05	0.00249	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—JUN—psoriasis	6.47e-05	0.00247	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Clobetasol propionate—psoriasis	6.42e-05	0.0103	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Clobetasol propionate—psoriasis	6.42e-05	0.0103	CbGdCrCtD
Epirubicin—UGT2B7—Metabolism—CYP2S1—psoriasis	6.06e-05	0.00231	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP2S1—psoriasis	5.94e-05	0.00227	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—psoriasis	5.93e-05	0.00226	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—PCNA—psoriasis	5.91e-05	0.00225	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—STAT3—psoriasis	5.6e-05	0.00213	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NDUFA5—psoriasis	5.59e-05	0.00213	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HCAR2—psoriasis	5.5e-05	0.0021	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	5.43e-05	0.00207	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL6—psoriasis	5.4e-05	0.00206	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.32e-05	0.00203	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CAT—psoriasis	5.27e-05	0.00201	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.21e-05	0.00199	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	5.19e-05	0.00198	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Fluocinonide—psoriasis	5.14e-05	0.00823	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Beclomethasone—psoriasis	5.14e-05	0.00823	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Beclomethasone—psoriasis	5.14e-05	0.00823	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Fluocinonide—psoriasis	5.14e-05	0.00823	CbGdCrCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.12e-05	0.00195	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—JUN—psoriasis	5.11e-05	0.00195	CbGpPWpGaD
Epirubicin—PLA2G4A—Betamethasone—Fluocinolone Acetonide—psoriasis	5e-05	0.00799	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Fluocinolone Acetonide—psoriasis	5e-05	0.00799	CbGdCrCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.95e-05	0.00189	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL20—psoriasis	4.83e-05	0.00184	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TAGAP—psoriasis	4.76e-05	0.00182	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP2S1—psoriasis	4.75e-05	0.00181	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.65e-05	0.00177	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—PCNA—psoriasis	4.62e-05	0.00176	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.61e-05	0.00176	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.44e-05	0.00169	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—PCNA—psoriasis	4.13e-05	0.00158	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—APOE—psoriasis	4.1e-05	0.00156	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.03e-05	0.00154	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.98e-05	0.00152	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	3.58e-05	0.00137	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PPARG—psoriasis	3.57e-05	0.00136	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.51e-05	0.00134	CbGpPWpGaD
Epirubicin—Dermatitis—Mycophenolic acid—psoriasis	3.47e-05	0.000121	CcSEcCtD
Epirubicin—Pain—Prednisolone—psoriasis	3.47e-05	0.000121	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—psoriasis	3.47e-05	0.00012	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—psoriasis	3.47e-05	0.00012	CcSEcCtD
Epirubicin—Urticaria—Mycophenolate mofetil—psoriasis	3.46e-05	0.00012	CcSEcCtD
Epirubicin—Headache—Mycophenolic acid—psoriasis	3.45e-05	0.00012	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.45e-05	0.00132	CbGpPWpGaD
Epirubicin—Decreased appetite—Hydrocortisone—psoriasis	3.45e-05	0.00012	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—psoriasis	3.44e-05	0.00012	CcSEcCtD
Epirubicin—Body temperature increased—Mycophenolate mofetil—psoriasis	3.44e-05	0.000119	CcSEcCtD
Epirubicin—Abdominal pain—Mycophenolate mofetil—psoriasis	3.44e-05	0.000119	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—psoriasis	3.43e-05	0.000119	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.42e-05	0.000119	CcSEcCtD
Epirubicin—Fatigue—Hydrocortisone—psoriasis	3.42e-05	0.000119	CcSEcCtD
Epirubicin—Vision blurred—Prednisone—psoriasis	3.41e-05	0.000118	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—psoriasis	3.4e-05	0.000118	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.4e-05	0.000118	CcSEcCtD
Epirubicin—Pain—Hydrocortisone—psoriasis	3.39e-05	0.000118	CcSEcCtD
Epirubicin—Oedema—Betamethasone—psoriasis	3.39e-05	0.000118	CcSEcCtD
Epirubicin—Anaphylactic shock—Betamethasone—psoriasis	3.39e-05	0.000118	CcSEcCtD
Epirubicin—Anaphylactic shock—Dexamethasone—psoriasis	3.39e-05	0.000118	CcSEcCtD
Epirubicin—Oedema—Dexamethasone—psoriasis	3.39e-05	0.000118	CcSEcCtD
Epirubicin—Insomnia—Triamcinolone—psoriasis	3.38e-05	0.000117	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—psoriasis	3.37e-05	0.00129	CbGpPWpGaD
Epirubicin—Infection—Betamethasone—psoriasis	3.37e-05	0.000117	CcSEcCtD
Epirubicin—Infection—Dexamethasone—psoriasis	3.37e-05	0.000117	CcSEcCtD
Epirubicin—Ill-defined disorder—Prednisone—psoriasis	3.35e-05	0.000116	CcSEcCtD
Epirubicin—Paraesthesia—Triamcinolone—psoriasis	3.35e-05	0.000116	CcSEcCtD
Epirubicin—Feeling abnormal—Prednisolone—psoriasis	3.35e-05	0.000116	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—psoriasis	3.34e-05	0.000116	CcSEcCtD
Epirubicin—Anaemia—Prednisone—psoriasis	3.34e-05	0.000116	CcSEcCtD
Epirubicin—Shock—Dexamethasone—psoriasis	3.33e-05	0.000116	CcSEcCtD
Epirubicin—Shock—Betamethasone—psoriasis	3.33e-05	0.000116	CcSEcCtD
Epirubicin—Dyspnoea—Triamcinolone—psoriasis	3.33e-05	0.000116	CcSEcCtD
Epirubicin—Nervous system disorder—Dexamethasone—psoriasis	3.32e-05	0.000115	CcSEcCtD
Epirubicin—Nervous system disorder—Betamethasone—psoriasis	3.32e-05	0.000115	CcSEcCtD
Epirubicin—Agitation—Prednisone—psoriasis	3.32e-05	0.000115	CcSEcCtD
Epirubicin—Thrombocytopenia—Betamethasone—psoriasis	3.32e-05	0.000115	CcSEcCtD
Epirubicin—Thrombocytopenia—Dexamethasone—psoriasis	3.32e-05	0.000115	CcSEcCtD
Epirubicin—Tachycardia—Betamethasone—psoriasis	3.31e-05	0.000115	CcSEcCtD
Epirubicin—Tachycardia—Dexamethasone—psoriasis	3.31e-05	0.000115	CcSEcCtD
Epirubicin—Hypersensitivity—Cyclosporine—psoriasis	3.29e-05	0.000114	CcSEcCtD
Epirubicin—Dyspepsia—Triamcinolone—psoriasis	3.29e-05	0.000114	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—psoriasis	3.28e-05	0.000114	CcSEcCtD
Epirubicin—Nausea—Mycophenolic acid—psoriasis	3.28e-05	0.000114	CcSEcCtD
Epirubicin—Hyperhidrosis—Dexamethasone—psoriasis	3.27e-05	0.000114	CcSEcCtD
Epirubicin—Hyperhidrosis—Betamethasone—psoriasis	3.27e-05	0.000114	CcSEcCtD
Epirubicin—Feeling abnormal—Hydrocortisone—psoriasis	3.27e-05	0.000113	CcSEcCtD
Epirubicin—Malaise—Prednisone—psoriasis	3.26e-05	0.000113	CcSEcCtD
Epirubicin—Vertigo—Prednisone—psoriasis	3.25e-05	0.000113	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—psoriasis	3.24e-05	0.000113	CcSEcCtD
Epirubicin—Gastrointestinal pain—Hydrocortisone—psoriasis	3.24e-05	0.000113	CcSEcCtD
Epirubicin—Syncope—Prednisone—psoriasis	3.24e-05	0.000113	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—psoriasis	3.24e-05	0.000112	CcSEcCtD
Epirubicin—Anorexia—Betamethasone—psoriasis	3.23e-05	0.000112	CcSEcCtD
Epirubicin—Anorexia—Dexamethasone—psoriasis	3.23e-05	0.000112	CcSEcCtD
Epirubicin—Urticaria—Prednisolone—psoriasis	3.22e-05	0.000112	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—psoriasis	3.22e-05	0.000112	CcSEcCtD
Epirubicin—Fatigue—Triamcinolone—psoriasis	3.22e-05	0.000112	CcSEcCtD
Epirubicin—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.21e-05	0.000111	CcSEcCtD
Epirubicin—Asthenia—Cyclosporine—psoriasis	3.2e-05	0.000111	CcSEcCtD
Epirubicin—Pain—Triamcinolone—psoriasis	3.19e-05	0.000111	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—NOS2—psoriasis	3.19e-05	0.00122	CbGpPWpGaD
Epirubicin—Loss of consciousness—Prednisone—psoriasis	3.18e-05	0.00011	CcSEcCtD
Epirubicin—Hypotension—Betamethasone—psoriasis	3.17e-05	0.00011	CcSEcCtD
Epirubicin—Hypotension—Dexamethasone—psoriasis	3.17e-05	0.00011	CcSEcCtD
Epirubicin—Pruritus—Cyclosporine—psoriasis	3.16e-05	0.00011	CcSEcCtD
Epirubicin—Urticaria—Hydrocortisone—psoriasis	3.15e-05	0.000109	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—psoriasis	3.15e-05	0.000109	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—psoriasis	3.13e-05	0.000109	CcSEcCtD
Epirubicin—Abdominal pain—Hydrocortisone—psoriasis	3.13e-05	0.000109	CcSEcCtD
Epirubicin—Body temperature increased—Hydrocortisone—psoriasis	3.13e-05	0.000109	CcSEcCtD
Epirubicin—Convulsion—Prednisone—psoriasis	3.13e-05	0.000109	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—psoriasis	3.13e-05	0.000109	CcSEcCtD
Epirubicin—Asthenia—Mycophenolate mofetil—psoriasis	3.12e-05	0.000108	CcSEcCtD
Epirubicin—Hypertension—Prednisone—psoriasis	3.12e-05	0.000108	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.11e-05	0.00119	CbGpPWpGaD
Epirubicin—Chills—Methotrexate—psoriasis	3.11e-05	0.000108	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Betamethasone—psoriasis	3.09e-05	0.000107	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.09e-05	0.000107	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—IL6—psoriasis	3.09e-05	0.00118	CbGpPWpGaD
Epirubicin—Pruritus—Mycophenolate mofetil—psoriasis	3.08e-05	0.000107	CcSEcCtD
Epirubicin—Myalgia—Prednisone—psoriasis	3.08e-05	0.000107	CcSEcCtD
Epirubicin—Arthralgia—Prednisone—psoriasis	3.08e-05	0.000107	CcSEcCtD
Epirubicin—Feeling abnormal—Triamcinolone—psoriasis	3.08e-05	0.000107	CcSEcCtD
Epirubicin—Anxiety—Prednisone—psoriasis	3.07e-05	0.000106	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—psoriasis	3.07e-05	0.000106	CcSEcCtD
Epirubicin—Insomnia—Dexamethasone—psoriasis	3.06e-05	0.000106	CcSEcCtD
Epirubicin—Insomnia—Betamethasone—psoriasis	3.06e-05	0.000106	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.06e-05	0.000106	CcSEcCtD
Epirubicin—Diarrhoea—Cyclosporine—psoriasis	3.05e-05	0.000106	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.04e-05	0.00116	CbGpPWpGaD
Epirubicin—Paraesthesia—Dexamethasone—psoriasis	3.04e-05	0.000106	CcSEcCtD
Epirubicin—Paraesthesia—Betamethasone—psoriasis	3.04e-05	0.000106	CcSEcCtD
Epirubicin—Discomfort—Prednisone—psoriasis	3.04e-05	0.000106	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—psoriasis	3.04e-05	0.000106	CcSEcCtD
Epirubicin—Erythema—Methotrexate—psoriasis	3.02e-05	0.000105	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—psoriasis	3.02e-05	0.000105	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisolone—psoriasis	2.99e-05	0.000104	CcSEcCtD
Epirubicin—Dyspepsia—Dexamethasone—psoriasis	2.98e-05	0.000104	CcSEcCtD
Epirubicin—Dyspepsia—Betamethasone—psoriasis	2.98e-05	0.000104	CcSEcCtD
Epirubicin—Diarrhoea—Mycophenolate mofetil—psoriasis	2.98e-05	0.000103	CcSEcCtD
Epirubicin—Urticaria—Triamcinolone—psoriasis	2.97e-05	0.000103	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CARM1—psoriasis	2.96e-05	0.00113	CbGpPWpGaD
Epirubicin—Dysgeusia—Methotrexate—psoriasis	2.96e-05	0.000103	CcSEcCtD
Epirubicin—Body temperature increased—Triamcinolone—psoriasis	2.95e-05	0.000102	CcSEcCtD
Epirubicin—Dizziness—Cyclosporine—psoriasis	2.95e-05	0.000102	CcSEcCtD
Epirubicin—Oedema—Prednisone—psoriasis	2.95e-05	0.000102	CcSEcCtD
Epirubicin—Anaphylactic shock—Prednisone—psoriasis	2.95e-05	0.000102	CcSEcCtD
Epirubicin—Decreased appetite—Betamethasone—psoriasis	2.94e-05	0.000102	CcSEcCtD
Epirubicin—Decreased appetite—Dexamethasone—psoriasis	2.94e-05	0.000102	CcSEcCtD
Epirubicin—Infection—Prednisone—psoriasis	2.93e-05	0.000102	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Betamethasone—psoriasis	2.92e-05	0.000102	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Dexamethasone—psoriasis	2.92e-05	0.000102	CcSEcCtD
Epirubicin—Back pain—Methotrexate—psoriasis	2.92e-05	0.000101	CcSEcCtD
Epirubicin—Hypersensitivity—Hydrocortisone—psoriasis	2.92e-05	0.000101	CcSEcCtD
Epirubicin—Fatigue—Dexamethasone—psoriasis	2.92e-05	0.000101	CcSEcCtD
Epirubicin—Fatigue—Betamethasone—psoriasis	2.92e-05	0.000101	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CARM1—psoriasis	2.9e-05	0.00111	CbGpPWpGaD
Epirubicin—Shock—Prednisone—psoriasis	2.9e-05	0.000101	CcSEcCtD
Epirubicin—Pain—Dexamethasone—psoriasis	2.9e-05	0.000101	CcSEcCtD
Epirubicin—Pain—Betamethasone—psoriasis	2.9e-05	0.000101	CcSEcCtD
Epirubicin—Nervous system disorder—Prednisone—psoriasis	2.89e-05	0.0001	CcSEcCtD
Epirubicin—Tachycardia—Prednisone—psoriasis	2.88e-05	0.0001	CcSEcCtD
Epirubicin—Dizziness—Mycophenolate mofetil—psoriasis	2.88e-05	9.99e-05	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—psoriasis	2.87e-05	0.00109	CbGpPWpGaD
Epirubicin—Skin disorder—Prednisone—psoriasis	2.87e-05	9.95e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CCL20—psoriasis	2.85e-05	0.00109	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Prednisone—psoriasis	2.85e-05	9.9e-05	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—psoriasis	2.85e-05	9.88e-05	CcSEcCtD
Epirubicin—Asthenia—Hydrocortisone—psoriasis	2.84e-05	9.88e-05	CcSEcCtD
Epirubicin—Vomiting—Cyclosporine—psoriasis	2.84e-05	9.85e-05	CcSEcCtD
Epirubicin—Rash—Cyclosporine—psoriasis	2.81e-05	9.77e-05	CcSEcCtD
Epirubicin—Anorexia—Prednisone—psoriasis	2.81e-05	9.76e-05	CcSEcCtD
Epirubicin—Dermatitis—Cyclosporine—psoriasis	2.81e-05	9.76e-05	CcSEcCtD
Epirubicin—Pruritus—Hydrocortisone—psoriasis	2.8e-05	9.74e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—psoriasis	2.8e-05	9.73e-05	CcSEcCtD
Epirubicin—Headache—Cyclosporine—psoriasis	2.79e-05	9.7e-05	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—psoriasis	2.79e-05	9.69e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Betamethasone—psoriasis	2.79e-05	9.69e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Dexamethasone—psoriasis	2.79e-05	9.69e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Betamethasone—psoriasis	2.77e-05	9.62e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Dexamethasone—psoriasis	2.77e-05	9.62e-05	CcSEcCtD
Epirubicin—Vomiting—Mycophenolate mofetil—psoriasis	2.77e-05	9.61e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Triamcinolone—psoriasis	2.75e-05	9.55e-05	CcSEcCtD
Epirubicin—Rash—Mycophenolate mofetil—psoriasis	2.74e-05	9.53e-05	CcSEcCtD
Epirubicin—Dermatitis—Mycophenolate mofetil—psoriasis	2.74e-05	9.52e-05	CcSEcCtD
Epirubicin—Headache—Mycophenolate mofetil—psoriasis	2.73e-05	9.47e-05	CcSEcCtD
Epirubicin—Malaise—Methotrexate—psoriasis	2.72e-05	9.46e-05	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—psoriasis	2.71e-05	9.42e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.71e-05	0.00103	CbGpPWpGaD
Epirubicin—Diarrhoea—Hydrocortisone—psoriasis	2.71e-05	9.42e-05	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—psoriasis	2.7e-05	9.39e-05	CcSEcCtD
Epirubicin—Urticaria—Dexamethasone—psoriasis	2.69e-05	9.34e-05	CcSEcCtD
Epirubicin—Urticaria—Betamethasone—psoriasis	2.69e-05	9.34e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Prednisone—psoriasis	2.69e-05	9.33e-05	CcSEcCtD
Epirubicin—Dizziness—Prednisolone—psoriasis	2.68e-05	9.32e-05	CcSEcCtD
Epirubicin—Asthenia—Triamcinolone—psoriasis	2.68e-05	9.3e-05	CcSEcCtD
Epirubicin—Body temperature increased—Dexamethasone—psoriasis	2.68e-05	9.3e-05	CcSEcCtD
Epirubicin—Abdominal pain—Betamethasone—psoriasis	2.68e-05	9.3e-05	CcSEcCtD
Epirubicin—Abdominal pain—Dexamethasone—psoriasis	2.68e-05	9.3e-05	CcSEcCtD
Epirubicin—Body temperature increased—Betamethasone—psoriasis	2.68e-05	9.3e-05	CcSEcCtD
Epirubicin—Insomnia—Prednisone—psoriasis	2.67e-05	9.26e-05	CcSEcCtD
Epirubicin—Nausea—Cyclosporine—psoriasis	2.65e-05	9.2e-05	CcSEcCtD
Epirubicin—Paraesthesia—Prednisone—psoriasis	2.65e-05	9.2e-05	CcSEcCtD
Epirubicin—Pruritus—Triamcinolone—psoriasis	2.64e-05	9.17e-05	CcSEcCtD
Epirubicin—Cough—Methotrexate—psoriasis	2.64e-05	9.15e-05	CcSEcCtD
Epirubicin—Dizziness—Hydrocortisone—psoriasis	2.62e-05	9.1e-05	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—psoriasis	2.62e-05	9.09e-05	CcSEcCtD
Epirubicin—Dyspepsia—Prednisone—psoriasis	2.6e-05	9.02e-05	CcSEcCtD
Epirubicin—Nausea—Mycophenolate mofetil—psoriasis	2.58e-05	8.98e-05	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—psoriasis	2.57e-05	8.93e-05	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—psoriasis	2.57e-05	8.93e-05	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—psoriasis	2.57e-05	8.93e-05	CcSEcCtD
Epirubicin—Decreased appetite—Prednisone—psoriasis	2.56e-05	8.9e-05	CcSEcCtD
Epirubicin—Rash—Prednisolone—psoriasis	2.56e-05	8.89e-05	CcSEcCtD
Epirubicin—Dermatitis—Prednisolone—psoriasis	2.56e-05	8.88e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.55e-05	8.87e-05	CcSEcCtD
Epirubicin—Fatigue—Prednisone—psoriasis	2.54e-05	8.83e-05	CcSEcCtD
Epirubicin—Headache—Prednisolone—psoriasis	2.54e-05	8.83e-05	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—psoriasis	2.54e-05	8.82e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Hydrocortisone—psoriasis	2.52e-05	0.00404	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Hydrocortisone—psoriasis	2.52e-05	0.00404	CbGdCrCtD
Epirubicin—Constipation—Prednisone—psoriasis	2.52e-05	8.76e-05	CcSEcCtD
Epirubicin—Vomiting—Hydrocortisone—psoriasis	2.52e-05	8.75e-05	CcSEcCtD
Epirubicin—Rash—Hydrocortisone—psoriasis	2.5e-05	8.68e-05	CcSEcCtD
Epirubicin—Dermatitis—Hydrocortisone—psoriasis	2.5e-05	8.67e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.49e-05	0.000949	CbGpPWpGaD
Epirubicin—Confusional state—Methotrexate—psoriasis	2.49e-05	8.63e-05	CcSEcCtD
Epirubicin—Headache—Hydrocortisone—psoriasis	2.48e-05	8.62e-05	CcSEcCtD
Epirubicin—Dizziness—Triamcinolone—psoriasis	2.47e-05	8.57e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—psoriasis	2.47e-05	8.56e-05	CcSEcCtD
Epirubicin—Infection—Methotrexate—psoriasis	2.45e-05	8.5e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Prednisone—psoriasis	2.43e-05	8.44e-05	CcSEcCtD
Epirubicin—Asthenia—Dexamethasone—psoriasis	2.43e-05	8.44e-05	CcSEcCtD
Epirubicin—Asthenia—Betamethasone—psoriasis	2.43e-05	8.44e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—psoriasis	2.42e-05	8.39e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—psoriasis	2.41e-05	8.38e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Prednisone—psoriasis	2.41e-05	8.38e-05	CcSEcCtD
Epirubicin—Nausea—Prednisolone—psoriasis	2.41e-05	8.37e-05	CcSEcCtD
Epirubicin—Pruritus—Dexamethasone—psoriasis	2.4e-05	8.32e-05	CcSEcCtD
Epirubicin—Pruritus—Betamethasone—psoriasis	2.4e-05	8.32e-05	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—psoriasis	2.39e-05	8.31e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—psoriasis	2.38e-05	8.28e-05	CcSEcCtD
Epirubicin—Vomiting—Triamcinolone—psoriasis	2.37e-05	8.24e-05	CcSEcCtD
Epirubicin—Nausea—Hydrocortisone—psoriasis	2.35e-05	8.18e-05	CcSEcCtD
Epirubicin—Rash—Triamcinolone—psoriasis	2.35e-05	8.17e-05	CcSEcCtD
Epirubicin—Dermatitis—Triamcinolone—psoriasis	2.35e-05	8.17e-05	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—psoriasis	2.35e-05	8.16e-05	CcSEcCtD
Epirubicin—Urticaria—Prednisone—psoriasis	2.34e-05	8.14e-05	CcSEcCtD
Epirubicin—PLA2G4A—Betamethasone—Dexamethasone—psoriasis	2.34e-05	0.00375	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Betamethasone—psoriasis	2.34e-05	0.00375	CbGdCrCtD
Epirubicin—Headache—Triamcinolone—psoriasis	2.34e-05	8.12e-05	CcSEcCtD
Epirubicin—Abdominal pain—Prednisone—psoriasis	2.33e-05	8.1e-05	CcSEcCtD
Epirubicin—Body temperature increased—Prednisone—psoriasis	2.33e-05	8.1e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CARM1—psoriasis	2.32e-05	0.000885	CbGpPWpGaD
Epirubicin—Diarrhoea—Betamethasone—psoriasis	2.32e-05	8.05e-05	CcSEcCtD
Epirubicin—Diarrhoea—Dexamethasone—psoriasis	2.32e-05	8.05e-05	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—psoriasis	2.3e-05	8e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Triamcinolone—psoriasis	2.29e-05	0.00366	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Triamcinolone—psoriasis	2.29e-05	0.00366	CbGdCrCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—psoriasis	2.25e-05	7.8e-05	CcSEcCtD
Epirubicin—Dizziness—Betamethasone—psoriasis	2.24e-05	7.78e-05	CcSEcCtD
Epirubicin—Dizziness—Dexamethasone—psoriasis	2.24e-05	7.78e-05	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—psoriasis	2.23e-05	7.74e-05	CcSEcCtD
Epirubicin—Nausea—Triamcinolone—psoriasis	2.22e-05	7.7e-05	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—psoriasis	2.21e-05	7.69e-05	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—psoriasis	2.2e-05	7.63e-05	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—psoriasis	2.19e-05	7.61e-05	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TP53—psoriasis	2.17e-05	0.000829	CbGpPWpGaD
Epirubicin—Hypersensitivity—Prednisone—psoriasis	2.17e-05	7.55e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisone—psoriasis	2.17e-05	0.00348	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisone—psoriasis	2.17e-05	0.00348	CbGdCrCtD
Epirubicin—Dyspepsia—Methotrexate—psoriasis	2.17e-05	7.53e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.17e-05	0.000827	CbGpPWpGaD
Epirubicin—Vomiting—Dexamethasone—psoriasis	2.15e-05	7.48e-05	CcSEcCtD
Epirubicin—Vomiting—Betamethasone—psoriasis	2.15e-05	7.48e-05	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—psoriasis	2.14e-05	7.44e-05	CcSEcCtD
Epirubicin—Rash—Betamethasone—psoriasis	2.14e-05	7.42e-05	CcSEcCtD
Epirubicin—Rash—Dexamethasone—psoriasis	2.14e-05	7.42e-05	CcSEcCtD
Epirubicin—Dermatitis—Betamethasone—psoriasis	2.13e-05	7.41e-05	CcSEcCtD
Epirubicin—Dermatitis—Dexamethasone—psoriasis	2.13e-05	7.41e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—psoriasis	2.13e-05	7.39e-05	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—psoriasis	2.13e-05	7.38e-05	CcSEcCtD
Epirubicin—Headache—Betamethasone—psoriasis	2.12e-05	7.37e-05	CcSEcCtD
Epirubicin—Headache—Dexamethasone—psoriasis	2.12e-05	7.37e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisolone—psoriasis	2.12e-05	0.00339	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisolone—psoriasis	2.12e-05	0.00339	CbGdCrCtD
Epirubicin—Asthenia—Prednisone—psoriasis	2.12e-05	7.35e-05	CcSEcCtD
Epirubicin—Pain—Methotrexate—psoriasis	2.11e-05	7.32e-05	CcSEcCtD
Epirubicin—Pruritus—Prednisone—psoriasis	2.09e-05	7.25e-05	CcSEcCtD
Epirubicin—TOP2A—Methyltestosterone—Hydrocortisone—psoriasis	2.07e-05	0.00331	CbGdCrCtD
Epirubicin—Feeling abnormal—Methotrexate—psoriasis	2.03e-05	7.05e-05	CcSEcCtD
Epirubicin—Diarrhoea—Prednisone—psoriasis	2.02e-05	7.01e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—psoriasis	2.02e-05	7e-05	CcSEcCtD
Epirubicin—Nausea—Dexamethasone—psoriasis	2.01e-05	6.99e-05	CcSEcCtD
Epirubicin—Nausea—Betamethasone—psoriasis	2.01e-05	6.99e-05	CcSEcCtD
Epirubicin—Urticaria—Methotrexate—psoriasis	1.96e-05	6.8e-05	CcSEcCtD
Epirubicin—Dizziness—Prednisone—psoriasis	1.95e-05	6.77e-05	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—psoriasis	1.95e-05	6.77e-05	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—psoriasis	1.95e-05	6.77e-05	CcSEcCtD
Epirubicin—Vomiting—Prednisone—psoriasis	1.88e-05	6.51e-05	CcSEcCtD
Epirubicin—Rash—Prednisone—psoriasis	1.86e-05	6.46e-05	CcSEcCtD
Epirubicin—Dermatitis—Prednisone—psoriasis	1.86e-05	6.45e-05	CcSEcCtD
Epirubicin—Headache—Prednisone—psoriasis	1.85e-05	6.42e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—psoriasis	1.85e-05	0.000704	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CAT—psoriasis	1.82e-05	0.000694	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—psoriasis	1.82e-05	6.31e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CAT—psoriasis	1.79e-05	0.000681	CbGpPWpGaD
Epirubicin—TOP2A—Methyltestosterone—Prednisone—psoriasis	1.78e-05	0.00285	CbGdCrCtD
Epirubicin—Asthenia—Methotrexate—psoriasis	1.77e-05	6.14e-05	CcSEcCtD
Epirubicin—Nausea—Prednisone—psoriasis	1.75e-05	6.08e-05	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—psoriasis	1.74e-05	6.06e-05	CcSEcCtD
Epirubicin—TOP2A—Methyltestosterone—Prednisolone—psoriasis	1.74e-05	0.00278	CbGdCrCtD
Epirubicin—Diarrhoea—Methotrexate—psoriasis	1.69e-05	5.86e-05	CcSEcCtD
Epirubicin—Dizziness—Methotrexate—psoriasis	1.63e-05	5.66e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SOCS1—psoriasis	1.57e-05	0.0006	CbGpPWpGaD
Epirubicin—Vomiting—Methotrexate—psoriasis	1.57e-05	5.44e-05	CcSEcCtD
Epirubicin—Rash—Methotrexate—psoriasis	1.55e-05	5.4e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—psoriasis	1.55e-05	5.39e-05	CcSEcCtD
Epirubicin—Headache—Methotrexate—psoriasis	1.54e-05	5.36e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—psoriasis	1.52e-05	0.00058	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—TYK2—psoriasis	1.5e-05	0.000572	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—psoriasis	1.46e-05	5.08e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CAT—psoriasis	1.43e-05	0.000544	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HLA-A—psoriasis	1.42e-05	0.000541	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—APOE—psoriasis	1.41e-05	0.00054	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—psoriasis	1.4e-05	0.000532	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—APOE—psoriasis	1.39e-05	0.000529	CbGpPWpGaD
Epirubicin—TOP2A—Norethindrone—Hydrocortisone—psoriasis	1.35e-05	0.00216	CbGdCrCtD
Epirubicin—ABCC1—Disease—APOE—psoriasis	1.32e-05	0.000505	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—psoriasis	1.3e-05	0.000498	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOS2—psoriasis	1.23e-05	0.00047	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPARG—psoriasis	1.23e-05	0.00047	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PPARG—psoriasis	1.21e-05	0.000461	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—LEP—psoriasis	1.16e-05	0.000442	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APOE—psoriasis	1.16e-05	0.000442	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—APOE—psoriasis	1.11e-05	0.000423	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NFKBIA—psoriasis	1.08e-05	0.000412	CbGpPWpGaD
Epirubicin—TOP2A—Levonorgestrel—Hydrocortisone—psoriasis	1.07e-05	0.00172	CbGdCrCtD
Epirubicin—ABCC1—Disease—TYK2—psoriasis	1.01e-05	0.000385	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPARG—psoriasis	9.65e-06	0.000368	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD4—psoriasis	9.14e-06	0.000348	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TYK2—psoriasis	8.85e-06	0.000338	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—psoriasis	7.71e-06	0.000294	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—psoriasis	7.33e-06	0.00028	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—psoriasis	7.17e-06	0.000273	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—psoriasis	7.07e-06	0.00027	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NFKB1—psoriasis	6.9e-06	0.000263	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—psoriasis	6.26e-06	0.000239	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—psoriasis	6.2e-06	0.000236	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—psoriasis	4.94e-06	0.000188	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—psoriasis	4.73e-06	0.00018	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—psoriasis	4.33e-06	0.000165	CbGpPWpGaD
